Laboratory Corp Of America Holdings's market capitalization of $19,622,204,000 is ahead of 89.89% of US-listed equities.
With a one year PEG ratio of 126.07, Laboratory Corp Of America Holdings is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 78.13% of US stocks.
LH's went public 30.7 years ago, making it older than 84.32% of listed US stocks we're tracking.
Stocks that are quantitatively similar to LH, based on their financial statements, market capitalization, and price volatility, are NDAQ, FOXA, BKI, TRU, and VIAC.
LH's SEC filings can be seen here. And to visit Laboratory Corp Of America Holdings's official web site, go to www.labcorp.com.
Laboratory Corporation of America Holdings (LH) Company Bio
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. The company offers a range of clinical laboratory tests and procedures, such as blood chemistry analysis, urinalysis, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, PSA, STD tests, HCV tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of diseases. The company was founded in 1971 and is based in Burlington, North Carolina.
LH Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Laboratory Corp Of America Holdings. To summarize, we found that Laboratory Corp Of America Holdings ranked in the 60th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 80.5%. The most interesting components of our discounted cash flow analysis for Laboratory Corp Of America Holdings ended up being:
Laboratory Corp Of America Holdings's weighted average cost of capital (WACC) is 7%; for context, that number is higher than merely 12.53% of tickers in our DCF set.
LH's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than merely 12.53% of tickers in our DCF set.
As a business, Laboratory Corp Of America Holdings experienced a tax rate of about 22% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than 84.83% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
ANIP, UTHR, HCSG, DGX, and PBH can be thought of as valuation peers to LH, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
The FDA has signed off on emergency use of LabCorp's (LH) high-throughput method using heat and technology to extract RNA from swab samples for SARS-CoV-2 molecular testing. The company says the heat extraction process, which eliminates the need for RNA extraction reagents, improves the speed and efficiency of real-time polymerase...
NY Governor Cuomo, in a briefing in NYC, announces that as part of the efforts related to school reopenings, NY will now require the publication of a daily "report card" for every school to give parents and teachers "confidence" about where their school stands in terms of potential outbreaks.The site...
LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced plans to create a program to offer total antibody testing at no charge through the patient’s doctor in support of increased blood plasma donations for use as a possible COVID-19 treatment.